A Quiet but Significant Docket
On May 13, 2026, the FDA opened docket FDA-2026-N-4492, a Request for Information on drug repurposing to address unmet medical needs. The press notice ran the same day. Comments are due by approximately June 29.
Most companies will file this docket alongside the daily warning-letter digest and never look at it again. That is a missed opportunity. The RFI is unusually specific about what the agency is asking for, and the answer it is looking for has substantive regulatory writing implications.
The docket specifically invites three categories of candidates:
Candidates where sufficient evidence may already exist to support a new use. Candidates with promising preliminary clinical data (case reports, case series, observational studies). Candidates with promising preliminary preclinical data, explicitly including findings from artificial intelligence and machine learning tools.
That third category is the one to read carefully. The agency is publicly acknowledging that AI-derived preclinical evidence has a role in identifying repurposing candidates worth pursuing. The implication for sponsors that have AI-derived signals sitting in unmonetised internal pipelines is that the FDA is asking, on the record, for those signals to be surfaced.
The Disease Areas That Matter
The RFI calls out five priority disease areas:
Metabolic diseases. Neurodegenerative conditions. Women's and men's health conditions. Substance use disorders. Rare diseases.
Plus "other areas stakeholders believe should be prioritized." The first four are the agency's stated priorities under MAHA-era policy. The fifth — rare diseases — is the area where repurposing has historically had the most regulatory traction, because the unmet need is documented and the commercial incentive is often the missing ingredient.
For sponsors with internal data on assets that could be repurposed into any of these areas, the docket is the cleanest formal channel to put those data on the agency's radar. A well-constructed comment includes the underlying scientific evidence, a development path proposal, and a clear statement of what regulatory action would be required.
Why the AI/ML Framing Matters
The explicit invitation for AI/ML preclinical evidence is a quiet but real shift. The FDA has been more comfortable than the public realises with AI-derived hypotheses for several years now. What the RFI does is make that comfort visible.
For regulatory writing teams, the implication is that AI-derived evidence is, formally and publicly, an acceptable input to a repurposing case. That changes what a competitive RFI response looks like. The strongest responses will not just say "we have AI signals" — they will lay out the AI methodology, the validation steps that were taken, the strength of the prediction, and how the AI evidence connects to subsequent biological or clinical follow-up.
This is the kind of evidence package that benefits from being written as a regulatory document rather than as a research summary. The conventions are different. The audience is different. The decision the evidence is being asked to support is different. Regulatory writing teams that can package AI-derived evidence in a regulator-readable form will produce stronger RFI responses than teams that try to translate research-team write-ups into regulatory language under deadline.
The Process Implication
Beyond the substance, the docket is also a leading indicator of how the agency wants to engage with industry on this topic. RFIs typically precede either guidance documents or formal pathway proposals. A high-quality response volume on this docket suggests the agency will issue a path forward — possibly a draft guidance on repurposing, possibly a structured submission process for repurposing candidates, possibly an expansion of an existing program like Project Renewal.
For sponsors with longer-term interest in repurposing as a development strategy, the RFI is also a chance to shape that path. The comment period is the leverage point. Submissions made between now and June 29 will be visible to the agency in a way that subsequent communications will not be.
The Practical Move for Sponsors
Three things to do in the next two weeks.
Survey internal pipelines for repurposing candidates that fit the five priority disease areas. Not just clinical-stage candidates — also preclinical and early-clinical assets where the data exists but the indication has not been prioritised commercially.
Decide which candidates to surface in the RFI response, if any. The RFI is public. Sponsors should think carefully about which assets they want to position publicly versus which they want to advance through other channels. Some candidates will be worth surfacing as part of the public record. Others will be worth keeping in proprietary engagement.
Write the response as a regulatory document. Engage the regulatory writing function in drafting. The response is being read by FDA staff. The conventions are regulatory writing conventions. A response written by a research team and reviewed by the regulatory function will read differently from one drafted with regulatory framing from the start.
The window is six weeks. The form is straightforward. The content takes real work to do well. Sponsors that treat the RFI as another bureaucratic input will miss the chance to shape what comes next.
What This Says About 2026
The Drug Repurposing RFI is the second meaningful public RFI from the agency this quarter. Combined with the Elsa 4.0 and HALO platform consolidation we wrote about last week, the CNPV pilot at seven approvals, and the active modernisation of internal review tooling, the agency is moving more visibly than it has in many years.
Sponsors that engage with these signals — by responding to dockets, by attending public hearings, by reading the cumulative patterns of approvals — will find themselves operating in a different regulatory environment than sponsors who do not.
The work is not glamorous. The comment, the hearing testimony, the careful read of the docket. It is also one of the highest-leverage uses of regulatory operations time available right now.